No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.
BACKGROUND
In a retrospective study of HIV patients under antiretroviral therapy, we investigated the influence of the MDR1 genotype (C3435T) on plasma levels of lopinavir (LPV) and efavirenz (EFV).


METHODS
The MDR1 genotype was analysed from 67 patients who were treated with LPV (n = 32; mean treatment period 53 weeks) and/or EFV (n = 43, mean treatment period 105 weeks) between 1999 and 2003. Plasma levels of LPV (trough levels) and EFV (12-h-levels) were determined every three months. Data were analysed by the Kruskal-Wallis test.


RESULTS
There were no significant differences in the LPV and EFV plasma levels with respect to the MDR1 3435 genotype.


CONCLUSIONS
We did not find evidence for an influence of the MDR1 3435 genotype on plasma levels of LPV and EFV.
Winzer
Ralf
R
Medical Policlinic, Division of Infectious Diseases, University of Würzburg, Germany. winzer_r@klinik.uni-wuerzburg.de
Langmann
P
P
Zilly
M
M
Tollmann
F
F
Schubert
J
J
Klinker
H
H
Weissbrich
B
B
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood* / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000097:blood* / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011744:Pyrimidinones / Q000097:blood* / Q000627:therapeutic use; D012189:Retrospective Studies
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D011744:Pyrimidinones; D061466:Lopinavir; C098320:efavirenz